MedPath

Comparing the effectiveness of Hypofractionated Radiotherapy with Conventional Radiotherapy in High Grade Glioma Treatment

Phase 2
Conditions
Health Condition 1: C719- Malignant neoplasm of brain, unspecified
Registration Number
CTRI/2024/01/061808
Lead Sponsor
AIIMS Raipur
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1 Pathologically proven high grade glioma (HGG).

2 Age = 50 years

3 Adequate routine blood investigations including complete blood count (CBC), liver function test (LFT) and renal function test (RFT)

Exclusion Criteria

Previous history of radiation to brain

Patient with metastatic disease

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
More patients treated with hypofractionated radiotherapy schedule will be able to complete treatment when compared to patients treated with the conventional schedule. <br/ ><br> <br/ ><br>The total dose given via hypofractionated schedule will be equivalent to the dose given via conventional fractionation (calculated from BED formula), hence will show a similar response. <br/ ><br>Timepoint: at treatment completion, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 20 weeks and 24 weeks post treatment completion
Secondary Outcome Measures
NameTimeMethod
Patients will be followed up post treatment and treatment toxicity assessment (RTOG criteria), neurological assessment (NANO criteria) and quality of life (QoL using QLQ- BN 20 assessment form)Timepoint: Baseline, Treatment completion, 1,2,3,4,5,6 months post treatment
© Copyright 2025. All Rights Reserved by MedPath